FERNANDO
PÉREZ RUIZ
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (2)
2017
-
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
Arthritis and Rheumatology, Vol. 69, Núm. 9, pp. 1903-1913
2016
-
Computational Lexical Analysis of the Language Commonly Used to Describe Gout
Arthritis Care and Research, Vol. 68, Núm. 6, pp. 763-768